Therapeutic potential of adenosine analogues and conjugates

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 601-617

  Samsel, Monika ^a   Dzierzbicka, Krystyna ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Adenosine conjugates; Adenosine receptors; Inhibitors of protein kinases

Indexed keywords

2 [6 [(2 HYDROXYCYCLOPENTYL)AMINO]PURIN 9 YL] 5 [(2 FLUOROPHENYLTHIO)METHYL]OXOLANE 3,4 DIOL; 5' CHLORO 5' DEOXY N6 (ENDO NORBORN 2 YL)ADENOSINE; 5' [(4 AMINO 2 BUTENYL)METHYLAMINO] 5' DEOXYADENOSINE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 METHYL 5' [(4 AMINOBUT 2 ENYL)(METHYLAMINO)]ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE DERIVATIVE; ANTIDIABETIC AGENT; ANTINOCICEPTIVE AGENT; ANTITRYPANOSOMAL AGENT; APADENOSON; BETA 2 ADRENERGIC RECEPTOR; BINODENOSON; CVT 3416; CVT 3619; ENZYME INHIBITOR; GENZ 644131; N 6 TETRAHYDOFURANYL 5' CHLORO 5' DEOXYADENOSINE; PLACEBO; PROTEIN KINASE INHIBITOR; REGADENOSON; SELODENOSON; SONEDENOSON; TECADENOSON; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIARRHYTHMIC ACTIVITY; ASTHMA; ATRIOVENTRICULAR BLOCK; BINDING AFFINITY; BRADYCARDIA; CHRONIC HEPATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACOLOGY; CORONARY ARTERY DISEASE; CROHN DISEASE; DIABETIC FOOT; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRY EYE; DYSPNEA; FLUSHING; GLAUCOMA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; KERATOCONJUNCTIVITIS; LIVER CELL CARCINOMA; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PAIN; PARASITOSIS; PNEUMONIA; PROTEIN BINDING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 80051495803     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70573-4     Document Type: Review

References (101)

1. A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma - Full Text View - Clinical-Trials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/NCT00790218?term=Cl-IB- MECA&rank=1.
2. A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/NCT00790673?term=Cl-IB- MECA&rank=2.
3. A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00837291?term=IB-MECA&rank=2.
4. Abdel-Hamid M, Novotny L, Hamza H: Stability study of selected adenosine nucleosides using LC and LC/MS analyses. J Pharm Biomed Anal, 2000, 22, 745-755. (Pubitemid 30193306)
5. Adachi H, Palaniappan KK, Ivanov AA, Bergman N, Gao ZG, Jacobson KA: Structure-activity relationships of 2,N(6),5′-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem, 2007, 50, 1810-1827. (Pubitemid 46626592)
6. Aderis Pharmaceuticals - News - Press Releases [Internet]. [cited 2010/08/02].Available from: http://www.aderis.com/news/releases.asp?display= detail&id=27
7. Aherne CM, Kewley EM, Eltzschig HK: The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta, 2011, 1808, 1329-1339.
8. Al Jaroudi W, Iskandrian AE: Regadenoson: a new myocardial stress agent. J Am Coll Cardiol, 2009, 54, 1123-1130.
9. Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N et al.: Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology, 2010, 117, 1287-1293.
10. Aurora J; Gill MS; Ong KKH: Pharmaceutical formulation for controlled release of selodenoson. Patent Application WO2005025545, 2005.
11. Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F et al.: The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol, 2008, 33, 287-295.
12. Baraldi PG, Preti D, Tabrizi MA, Fruttarolo F, Romagnoli R, Carrion MD, Cara LCL et al.: Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl) hydrazino]- 9H-purin-9-yl]-N-ethyl-β- D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. J Med Chem, 2007, 50, 374-380. (Pubitemid 46147717)
13. 2B adenosine receptor agonists. Purinergic Signal, 2009, 5, 3-19.
14. Barker RH, Liu H, Hirth B, Celatka CA, Fitzpatrick R, Xiang Y, Willert EK et al.: Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrob Agents Chemother, 2009, 53, 2052-2058.
15. Can-Fite BioPharma. Can-Fite BioPharma Receives Israeli MoH Approval to Conduct a Phase II Clinical Trial Evaluating the Efficacy of CF101 in Patients with Glaucoma [Internet]. [cited 2010/08/02]. Available from: http://www.canfite.com/pr/2010-05-23%20CF101%20Glaucoma%20MOH%20approval%20- %20English.pdf, Press Release.
16. Can-Fite BioPharma. Can-Fite's Drug CF102 Significantly Decreased Viral Load of HCV in a Patient with Liver Cancer. [Internet]. [cited 2010/07/27]. Available from: http://www.canfite.com/pr/2010-05-30%20CF102HCC%20anti-viral%20- %20English.pdf.
17. 1 receptor from different species. Bioorg Med Chem, 2008, 16, 336-353.
18. Cavalli A, Bolognesi ML: Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem, 2009, 52, 7339-7359.
19. Cerqueira MD: Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr Cardiol Rep, 2006, 8, 119-122.
20. 2BAR) on enteric neurons regulate murine distal colonic motility. FASEB J, 2009, 23, 2727-2734.
21. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci, 1999, 19, 9192-9200.
22. Clinical Data, Inc. Reports Results Of Phase I Studies Of Stedivaze™ Demonstrating Safety And Tolerability In Patients With Asthma And COPD [Internet]. [cited 2010/07/20]. Available from: http://www.pgxhealth. com/development/stedivaze.cfm.
23. Cunha RA: Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int, 2001, 38, 107-125.
24. CV Therapeutics Reports Phase 1 Data Showing Proof of Concept for CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases - Drugs.com MedNews [Internet]. [cited 2010/07/27]. Available from: http://www.drugs.com/ clinical-trials/cv-therapeutics-reports-phase-1-data-showing-proof-concept-cvt- 3619-novel-potential-cardiometabolic-6834.html#ixzz0u9e3lJY7.
25. Devine SM, Scammells PJ: An efficient convergent synthesis of adenosine-5′-N-alkyluronamides. Tetrahedron, 2008, 64, 1772-1777.
26. 1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther, 2007, 321, 327-333.
27. 1 adenosine receptor ligands. Curr Top Med Chem, 2003, 3, 369-385.
28. Dubey RK, Gillespie DG, Mi Z, Jackson EK: Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A2B receptors. Hypertension, 2005, 46, 628-634. (Pubitemid 41376846)
29. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK: A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood, 2008, 111, 2024-2035. (Pubitemid 351451513)
30. 2A receptor agonists activated by ecto-5′- nucleotidase. J Med Chem, 2009, 52, 7669-7677.
31. Ellenbogen KA, O'Neill G, Prystowsky EN, Camm JA, Meng L, Lieu HD, Jerling M et al.: Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation, 2005, 111, 3202-3208. (Pubitemid 40874990)
32. Elzein E, Zablocki J: A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs, 2008, 17, 1901-1910.
33. Enkvist E, Kriisa M, Roben M, Kadak G, Raidaru G, Uri A: Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases. Bioorg Med Chem Lett, 2009, 19, 6098-6101.
34. Enkvist E, Lavogina D, Raidaru G, Vaasa A, Viil I, Lust M, Viht K, Uri A: Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J Med Chem, 2006, 49, 7150-7159. (Pubitemid 44886000)
35. FDA Cardiorenal Panel Votes against Binodenoson [Internet]. CardioBrief, 2009, [cited 2010/07/20] Available from: http://cardiobrief.org/2009/07/28/fda- cardiorenal-panel-votes-against-binodenoson
36. 2B receptors. Pharmacol Rev, 1997, 49, 381-402.
37. 1adenosine receptor with antinociceptive effects in mice. J Med Chem, 2009, 52, 2393-2406.
38. 2Areceptors - where are they? What do they do? Trends Pharmacol Sci, 1998, 19, 46-47.
39. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev, 2001, 53, 527-552. (Pubitemid 33136237)
40. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP: Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol, 2009, 182, 4957-4964.
41. Gadgil S, Wheeler W, Mcdonald S, O'Dell S: Method of treating atrial fibrillation or atrial flutter. Patent Application WO2004100964, 2004.
42. Gessi S, Varani K, Merighi S, Fogli E, Sacchetto V, Benini A, Leung E et al.: Adenosine and lymphocyte regulation. Purinergic Signal, 2007, 3, 109-116.
43. Hack B, Witting PK, Rayner BS, Stocker R, Headrick JP: Oxidant stress and damage in post-ischemic mouse hearts: effects of adenosine. Mol Cell Biochem, 2006, 287, 165-175. (Pubitemid 44057404)
44. Hart ML, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK: Cutting Edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol, 2009, 182, 3965-3968.
45. Hirth B, Barker RH, Celatka CA, Klinger JD, Liu H, Nare B, Nijjar A et al.: Discovery of new S-adenosyl-methionine decarboxylase inhibitors for the treatment of Human African Trypanosomiasis (HAT). Bioorg Med Chem Lett, 2009, 19, 2916-2919.
46. Iino M, Ehama R, Nakazawa Y, Iwabuchi T, Ogo M, Tajima M, Arase S: Adenosine stimulates fibroblast growth factor-7 gene expression via adenosine A2b receptor signaling in dermal papilla cells. J Invest Dermatol, 2007, 127, 1318-1325. (Pubitemid 46762986)
47. Iskandrian AE: A new generation of coronary vasodilators in stress perfusion imaging. Am J Cardiol, 2007, 99, 1619-1620.
48. 1 and A3 adenosine receptor agonists: novel prototypes for cardioprotection. J Med Chem, 2005, 48, 8103-8107.
49. Jacobson K, Joshi B, Wang B, Klutz A, Kim Y, Ivanov A: Modified nucleosides as selective modulators of adenosine receptors for therapeutic use. In: Modified Nucleosides: in Biochemistry, Biotechnology and Medicine. Ed. Herdewijn PD, Wiley-VCH, Weinheim, 2008, 433-449.
50. 1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. Eur J Pharmacol, 2008, 597, 92-101.
51. Kaelin-Lang A, Lauterburg T, Burgunder JM: Expression of adenosine A2a receptors gene in the olfactory bulb and spinal cord of rat and mouse. Neurosci Lett, 1999, 261, 189-191. (Pubitemid 29104977)
52. 1receptor ligands. J Med Chem, 2008, 51, 6128-6137.
53. Kiesman W, Elzein E, Zablocki J: A1 adenosine receptor antagonists, agonists, and allosteric enhancers.In: Adenosine Receptors in Health and Disease. Eds. Wilson CN, Mustafa SJ, Springer-Verlag, Berlin, Heidelberg, 2009, Vol. 193, 25-58.
54. Koglin J, Stäblein A, von Scheidt W: Supersensitivity mismatch of adenosine in the transplanted human heart: chrono- and dromotropy vs. inotropy. Transpl Int, 1996, 9, 9-14. (Pubitemid 126509967)
55. 2B receptors ameliorates murine colitis. Br J Pharmacol, 2008, 155, 127-137.
56. Kumar V, Sharma A: Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol, 2009, 616, 7-15.
57. Lavogina D, Enkvist E, Uri A: Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem, 2010, 5, 23-34.
58. Lavogina D, Lust M, Viil I, König N, Raidaru G, Rogozina J, Enkvist E et al.: Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J Med Chem, 2009, 52, 308-321.
59. LeBoulluec KL, Mattson RJ, Mahle CD, McGovern RT, Nowak HP, Gentile AJ: Bivalent indoles exhibiting serotonergic binding affinity. Bioorg Med Chem Lett, 1995, 5, 123-126.
60. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J et al.: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature, 1997, 388, 674-678. (Pubitemid 27366438)
61. Leopoldo M, Lacivita E, Colabufo NA, Niso M, Berardi F, Perrone R: Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl) piperazine: synthesis and binding affinities for 5-HT7 and 5-HT1Areceptors. Bioorg Med Chem, 2007, 15, 5316-5321. (Pubitemid 46880366)
62. Li T, Steinbeck JA, Lusardi T, Koch P, Lan JQ, Wilz A, Segschneider M et al.: Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain, 2007, 130, 1276-1288. (Pubitemid 47355953)
63. Liang BT, Jacobson KA: A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci USA, 1998, 95, 6995-6999. (Pubitemid 28278095)
64. 1-adenosine receptor. Br J Pharmacol, 2002, 135, 1457-1466.
65. Loog M, Uri A, Raidaru G, Järv J, Ek P: Adenosine-5′- carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett, 1999, 9, 1447-1452. (Pubitemid 29232225)
66. 2A agonist on the allergen-induced late asthmatic response. Allergy, 2008, 63, 75-80.
67. Mantell S, Jones R, Trevethick M: Design and application of locally delivered agonists of the adenosine A2A receptor. Expert Rev Clin Pharmacol, 2010, 3, 55-72.
68. 2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorg Med Chem Lett, 2009, 19, 4471-4475.
69. Mathôt RA, van Schaick EA, Langemeijer MW, Soudijn W, Breimer DD, Ijzerman AP, Danhof M: Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther, 1994, 268, 616-624. (Pubitemid 24085855)
70. 3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care, 2006, 10, R65.
71. 2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis, 2008, 8, 141.
72. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74, 1124-1136. (Pubitemid 17174962)
73. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol, 2009, 258, 115-122.
74. Ohta A, Sitkovsky M: The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol, 2009, 9, 501-506.
75. Parang K, Cole PA: Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther, 2002, 93, 145-157. (Pubitemid 34615556)
76. Pereira GS, Rossato JI, Sarkis JJF, Cammarota M, Bonan CD, Izquierdo I: Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol Learn Mem, 2005, 83, 217-223. (Pubitemid 40488809)
77. Poulsen SA, Quinn RJ: Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem, 1998, 6, 619-641.
78. Prystowsky EN, Niazi I, Curtis AB, Wilber DJ, Bahnson T, Ellenbogen K, Dhala A et al.: Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol, 2003, 42, 1098-1102. (Pubitemid 37108600)
79. Reguera RM, Tekwani BL, Balaña-Fouce R: Polyamine transport in parasites: a potential target for new antiparasitic drug development. Comp Biochem Physiol C Toxicol Pharmacol, 2005, 140, 151-164. (Pubitemid 40720036)
80. Rimmer J, Peake HL, Santos CMC, Lean M, Bardin P, Robson R, Haumann B et al.: Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy, 2007, 37, 8-14. (Pubitemid 46011053)
81. Safety and Efficacy of UK-432,097 In Chronic Obstructive Pulmonary Disease. - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/NCT00430300?term=uk- 432%2C097&rank=1.
82. Safety Study of Tecadenoson to Treat Atrial Fibrillation - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/NCT00713401?term=tecadenoson&rank=1.
83. Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/ show/NCT00318214?term=MRE0094%27&rank=1.
84. Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/NCT00312364? term=MRE0094&rank=2.
85. Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/show/ NCT01033422?term=IB-MECA&rank=1.
86. Savelieva I, Camm J: Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace, 2008, 10, 647-665. (Pubitemid 351775283)
87. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I et al.: Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol, 2008, 35, 41-48.
88. Sorbera L, Castaner J, Martin L, Bayes M: Tecadenoson. Drugs Fut, 2002, 27, 846.
89. Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2010/07/27]. Available from: http://clinicaltrials.gov/ct2/ show/ NCT00990327?term=apadenoson&rank=1.
90. Sullivan GW: Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs, 2003, 4, 1313-1319.
91. 2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest, 2006, 116, 2173-2182.
92. Tostes RC, Giachini FRC, Carneiro FS, Leite R, Inscho EW, Webb RC: Determination of adenosine effects and adenosine receptors in murine corpus cavernosum. J Pharmacol Exp Ther, 2007, 322, 678-685. (Pubitemid 47105776)
93. Udelson JE, Iteld BJ, Weiland FL, Foster JB, Bonow RO, Ficaro EP, Gibbons R et al.: Double-blinded comparison of the side effects associated with pharmacologic stress induced with binodenoson and adenosine. J Nucl Cardiol, 2008, 15, S17-S18.
94. Von Lubitz DK, Lin RC, Popik P, Carter MF, Jacobson KA: Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol, 1994, 263, 59-67.
95. Wagner R, Ngamsri KC, Stark S, Vollmer I, Reutershan J: Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol, 2010, 299, L502-512.
96. Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ et al.: The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)- 3′amino-adenosine-5′-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther, 2008, 324, 234-243. (Pubitemid 350294150)
97. Willert EK, Phillips MA: Regulated expression of an essential allosteric activator of polyamine biosynthesis in African trypanosomes. PLoS Pathog, 2008, 4, e1000183.
98. Zhou Y, Mohsenin A, Morschl E, Young HWJ, Molina JG, Ma W, Sun CX et al.: Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol, 2009, 182, 8037-8046.
99. Zhou Y, Schneider DJ, Blackburn MR: Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther, 2009, 123, 105-116.
100. Zhu BT: Mechanistic explanation for the unique pharmacologic properties of receptor partial agonists. Biomed Pharmacother, 2005, 59, 76-89.
101. Zhu R, Frazier CR, Linden J, Macdonald TL: N6-ethyl- 2-alkynyl NECAs, selective human A3 adenosine receptor agonists. Bioorg Med Chem Lett, 2006, 16, 2416-2418.